HudsonAlpha faculty investigator Sara Cooper, PhD, focuses her research efforts on understanding mechanisms of cancer pathology, progression, and chemoresistance in an effort to help personalize cancer diagnosis and treatment.

The Cooper Lab uses various genomic approaches to explore and understand cancer, with the ultimate goal of identifying signatures associated with cancer and then implementing those signatures in a clinical setting. Overall, the Cooper lab is dedicated to the identification of novel therapeutic targets, and strategies for treating pancreatic and ovarian cancer, both of which have some of the worst outcomes among cancer patients.

The lab currently focuses its efforts on the following areas:

  • The identification of biomarkers of and novel targets to prevent cancer chemoresistance
  • The importance of immune response in cancer
  • The discovery of new genes that predispose individuals to cancer

Recent News

February 3, 2022
Scientists at HudsonAlpha published a paper in Clinical Cancer Research describing the results of a study that explored gene expression and metabolic signatures in ovarian cancer to discover both markers of treatment response and ...
June 3, 2021
The limited effectiveness of chemotherapy has led to a long effort in the scientific and medical communities to identify alternative treatment strategies. Scientists at HudsonAlpha recently contributed to this effort by publishing...
March 17, 2021
HudsonAlpha and The Links, Inc, (Greater Huntsville Chapter) will host two virtual events March 23 and April 6 at 6:30pm to discuss how genes can impact your health, healthcare disparities, and how genetic testing and participa...
Load More